MYOCURE SIGNED
Development of an innovative gene therapy platform to cure rare hereditary muscle disorders
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MYOCURE project word cloud
Explore the words cloud of the MYOCURE project. It provides you a very rough idea of what is the project "MYOCURE" about.
Project "MYOCURE" data sheet
The following table provides information about the project.
| Coordinator |
VRIJE UNIVERSITEIT BRUSSEL
Organization address contact info |
| Coordinator Country | Belgium [BE] |
| Project website | http://www.myocure.eu |
| Total cost | 5˙998˙937 € |
| EC max contribution | 5˙998˙937 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-PHC-2015-two-stage |
| Funding Scheme | RIA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-01-01 to 2019-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | VRIJE UNIVERSITEIT BRUSSEL | BE (BRUSSEL) | coordinator | 1˙101˙370.00 |
| 2 | ASSOCIATION GENETHON | FR (EVRY) | participant | 1˙437˙162.00 |
| 3 | ENVIGO CRS LIMITED | UK (HUNTINGDON) | participant | 1˙156˙500.00 |
| 4 | SORBONNE UNIVERSITE | FR (PARIS) | participant | 555˙175.00 |
| 5 | UNIVERSITATSKLINIKUM HEIDELBERG | DE (HEIDELBERG) | participant | 515˙250.00 |
| 6 | UNIVERSIDAD AUTONOMA DE BARCELONA | ES (CERDANYOLA DEL VALLES) | participant | 491˙730.00 |
| 7 | EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH | DE (ST INGBERT) | participant | 466˙750.00 |
| 8 | ASPHALION SL | ES (BARCELONA) | participant | 275˙000.00 |
| 9 | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 | FR (PARIS) | participant | 0.00 |
Map
Project objective
The objective of MYOCURE is to develop an innovative gene therapy platform to cure rare hereditary muscle disorders, specifically focusing on myotubular myopathy (MTM) and glycogen storage disorder (GSD) type II. These are attractive diseases for gene therapy since they compromise a diverse family of rare genetic diseases typically caused by single gene defects that often provoke significant morbidity and mortality due to skeletal muscle, cardiac and/or diaphragm dysfunction. There are no effective cures and current treatment is suboptimal. MYOCURE focuses specifically on overcoming the key bottlenecks that hamper muscle-directed gene therapy by (i) boosting gene transfer using muscle-specific adeno-associated viral vectors (AAV) generated de novo by directed molecular evolution (ii) increasing expression by using robust computationally designed muscle-specific promoters that are 400-fold more efficient than the state of the art, allowing the use of lower and thus safer therapeutic vector doses (iii) minimize undesirable immune reactions against the vector, gene-modified muscle cells and therapeutic proteins. The efficacy and safety of this advanced therapy medical product (ATMP) will be validated in preclinical MTM and GSD II animal models. A scalable manufacturing process will be developed for subsequent toxicology studies and an orphan drug designation will be applied for. MYOCURE will consolidate a roadmap towards clinical development and economic valorisation and maximize dissemination to the relevant stakeholders. The outcome of MYOCURE will constitute the basis of a Phase I gene therapy clinical trial in MTM and GSD patients consistent with the IRDiRC objectives to provide 200 therapies for rare disease by 2020. MYOCURE applies to 'PHC14 New Therapies for Rare Diseases' and advances the development of a new therapeutic option for patients suffering from these rare inherited muscle diseases, as well as related preclinical research and animal model development.
Deliverables
| Project website | Websites, patent fillings, videos etc. | 2020-01-30 08:49:24 |
Take a look to the deliverables list in detail: detailed list of MYOCURE deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Warut Tulalamba, Jonas Weinmann, Quang Hong Pham, Jihad El Andari, Thierry VandenDriessche, Marinee K. Chuah, Dirk Grimm Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors published pages: , ISSN: 0969-7128, DOI: 10.1038/s41434-019-0106-3 |
Gene Therapy | 2020-03-05 |
| 2019 |
S. Sarcar, W. Tulalamba, M. Y. Rincon, J. Tipanee, H. Q. Pham, H. Evens, D. Boon, E. Samara-Kuko, M. Keyaerts, M. Loperfido, E. Berardi, S. Jarmin, P. In’t Veld, G. Dickson, T. Lahoutte, M. Sampaolesi, P. De Bleser, T. VandenDriessche, M. K. Chuah Next-generation muscle-directed gene therapy by in silico vector design published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-08283-7 |
Nature Communications 10/1 | 2020-03-05 |
| 2017 |
Maria Luisa Jaén, Laia Vilà , Ivet Elias, Veronica Jimenez, Jordi Rodó, Luca Maggioni, Rafael Ruiz-de Gopegui, Miguel Garcia, Sergio Muñoz, David Callejas, Eduard Ayuso, Tura Ferré, Iris Grifoll, Anna Andaluz, Jesus Ruberte, Virginia Haurigot, Fatima Bosch Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs published pages: 1-7, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2017.03.008 |
Molecular Therapy - Methods & Clinical Development 6 | 2020-01-30 |
| 2017 |
Francesco Puzzo, Pasqualina Colella, Maria G. Biferi, Deeksha Bali, Nicole K. Paulk, Patrice Vidal, Fanny Collaud, Marcelo Simon-Sola, Severine Charles, Romain Hardet, Christian Leborgne, Amine Meliani, Mathilde Cohen-Tannoudji, Stephanie Astord, Bernard Gjata, Pauline Sellier, Laetitia van Wittenberghe, Alban Vignaud, Florence Boisgerault, Martine Barkats, Pascal Laforet, Mark A. Kay, Dwight D. Koeberl, Giuseppe Ronzitti, Federico Mingozzi Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase published pages: eaam6375, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aam6375 |
Science Translational Medicine 9/418 | 2020-01-30 |
| 2017 |
Dirk Grimm, Hildegard Büning Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution published pages: 1075-1086, ISSN: 1043-0342, DOI: 10.1089/hum.2017.172 |
Human Gene Therapy 28/11 | 2020-01-30 |
| 2018 |
Veronica Jimenez, Claudia Jambrina, Estefania Casana, Victor Sacristan, Sergio Muñoz, Sara Darriba, Jordi Rodó, Cristina Mallol, Miquel Garcia, Xavier León, Sara Marcó, Albert Ribera, Ivet Elias, Alba Casellas, Ignasi Grass, Gemma Elias, Tura Ferré, Sandra Motas, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Virginia Haurigot, Jesus Ruberte, Fatima Bosch FGF21 gene therapy as treatment for obesity and insulin resistance published pages: e8791, ISSN: 1757-4676, DOI: 10.15252/emmm.201708791 |
EMBO Molecular Medicine 10/8 | 2020-01-30 |
| 2019 |
Pasqualina Colella, Pauline Sellier, Helena Costa Verdera, Francesco Puzzo, Laetitia van Wittenberghe, Nicolas Guerchet, Nathalie Daniele, Bernard Gjata, Solenne Marmier, Severine Charles, Marcelo Simon Sola, Isabella Ragone, Christian Leborgne, Fanny Collaud, Federico Mingozzi AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice published pages: 85-101, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2018.11.002 |
Molecular Therapy - Methods & Clinical Development 12 | 2020-01-30 |
| 2018 |
Amine Meliani, Florence Boisgerault, Romain Hardet, Solenne Marmier, Fanny Collaud, Giuseppe Ronzitti, Christian Leborgne, Helena Costa Verdera, Marcelo Simon Sola, Severine Charles, Alban Vignaud, Laetitia van Wittenberghe, Giorgia Manni, Olivier Christophe, Francesca Fallarino, Christopher Roy, Alicia Michaud, Petr Ilyinskii, Takashi Kei Kishimoto, Federico Mingozzi Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-06621-3 |
Nature Communications 9/1 | 2020-01-30 |
| 2018 |
Klaudia Kuranda, Priscilla Jean-Alphonse, Christian Leborgne, Romain Hardet, Fanny Collaud, Solenne Marmier, Helena Costa Verdera, Giuseppe Ronzitti, Philippe Veron, Federico Mingozzi Exposure to wild-type AAV drives distinct capsid immunity profiles in humans published pages: 5267-5279, ISSN: 0021-9738, DOI: 10.1172/jci122372 |
Journal of Clinical Investigation 128/12 | 2020-01-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYOCURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MYOCURE" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
MISTRAL (2020)
Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination
Read MoreTT4CL (2019)
Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis
Read MoreHAP2 (2020)
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia
Read More